FREE PREVIEW
Semax and Selank
Human abstracts, animal research and translation limits.
AI-assisted editorial edition · Independent clinical review pending.
Before you read
This selected-source guide explains research for education. It is not a diagnosis, prescription or personal treatment plan. Do not start, stop or change medicines, combine products, or delay care because of this guide. Discuss proposed uses and interactions with a qualified clinician and pharmacist. It does not establish a clinician-patient relationship.
What this edition can and cannot answer
A selected-source research-reading edition separating animal/laboratory findings, human abstract records, product identities and unanswered clinical questions; no therapeutic or combination instructions.
- Animal behavioral tests, gene-expression changes and brain-imaging differences do not establish meaningful cognitive or anxiety benefit for a consumer.
- Key human reports remain abstract-only in the reviewed pilot; full methods, harms, cohort overlap and bilingual scientific review are incomplete. Separate-agent reports do not establish a Semax/Selank combination benefit.
- Bounded source closure checked 27 October 2026 using the named full reports, publisher/PubMed records and available companion documents. This is not a systematic literature search or exhaustive integrity review. Protocol comparisons and specified access, overlap and translation checks remain unfinished.
- AI-assisted editorial draft. Human editorial, qualified independent clinical, legal, reader-test and accessibility reviews are pending. Purchases and PDF downloads are not yet available.
SECTION 01
Semax and Selank
Cognition and anxiety claims often connect a biological signal to an everyday benefit. This guide shows where that connection is supported by a source and where human evidence still needs to be obtained and appraised. Use it to prepare a precise research question and a professional conversation.
Contents
SECTION 02
What the selected record can answer
| Source type | Concrete selected example | What remains unanswered |
|---|---|---|
| Human abstract [1] | Brain connectivity after Semax, Selank or placebo in healthy participants | Meaningful cognition, symptom relief and durability |
| Rat brain genes [2][3] | Gene-expression changes after experimental exposure | A reliable human benefit or established clinical mechanism |
| Rat behavior [4] | Selank and diazepam under stress and non-stress conditions; some non-stress indicators worsened | Vehicle and locomotion changes complicate interpretation; no human combination-safety conclusion |
| Human anxiety abstract [5] | Selank versus medazepam in anxiety/neurasthenia patients | Verified clinical magnitude, allocation, complete harms and durability |
This is an evidence map, not a ranking of products. Its purpose is to keep the model, intervention and measured endpoint attached to each statement. An animal result can justify another experiment without predicting the chance that a person will benefit.
Source-specific examples [1][2][3][4][5]; FDA context [6]. The connectomic report is one paper, not two independent studies. Qualified independent review remains pending.
SECTION 03
Sources, gaps and edition record
Selected sources; three rat reports checked in full. Human imaging (2020) and anxiety (2008) reports remain abstract-only. A duplicate imaging citation was merged. This is not a systematic review.
The selected reports leave unresolved human methods, harms and analysis gaps [1][5], plus bilingual and cohort checks for other clinical leads. No independent clinical, legal or translation approval is recorded.
Report a source or edition correction · Educational-use policy
FOLLOW THE EVIDENCE
Sources and reading limits
Panikratova et al. Functional Connectomic Approach to Studying Selank and Semax Effects (2020)
Human imaging example; separate-agent conditions.
PMID32342318; PubMed abstract and subscription publisher preview checked 27 October 2026; full report not acquired.
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
Rat ischemia gene-expression example; appraisal pending.
Results p2; Methods p10; printed abstract p1.
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Animal mechanism example; no clinical efficacy.
Gene-expression Results p3; rat frontal cortex identified p1.
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Rat behavior comparison; no human combination advice.
Abstract/Results p1; animal groups/routes p2.
Zozulia et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (2008)
62-patient active-comparator abstract; clinical methods/harms unresolved.
PMID18454096; Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38–48; PubMed abstract checked 27 October 2026; full report not acquired.
FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
United States compounding context; not global legal status.
Semax/Selank entries; checked 27 October 2026.
Edition and corrections
Web reading edition: 4 November 2026. Manuscript prepared: 2026-10-27. This web-format update does not represent a new literature search or completed clinical review.
Edition: PA-GUIDE-SEMAX-SELANK-2026-10-27-0.2-REVIEW-DRAFT
Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.
Report a correction →